A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
Status:
Unknown status
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This study is a randomized, controlled, open-label, prospective, single-center phase II
clinical study. Target population is patients with stage II and IIIA resectable non-small
cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate
the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with
resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal
antibody.